In: Digestion, 94 (2016), Nr. 3. pp. 129-137. ISSN 0012-2823 (Druck-Ausg.), 1421-9867 (Online-Ausg.)
PDF, English
- main document
Download (139kB) | Terms of use |
Abstract
Background/Aims: This study is aimed at analyzing the survival rates and prognostic factors of stage IV colorectal cancer patients from 3 European cohorts undergoing combination chemotherapy with bevacizumab.
Methods: Progression free-survival (PFS) and overall survival (OS) were analyzed in 172 patients using the Kaplan–Meier method and uni- and multivariable Cox proportional hazards regression models.
Results: The median PFS was 9.7 and the median OS 27.4 months. Patients treated at centers in Germany (n = 97), Ireland (n = 32), and The Netherlands (n = 43) showed a median PFS of 9.9, 9.2, and 9.7 months, OS of 34.0, 20.5, and 25.1 months, respectively. Patients >65 years had a significantly shorter PFS (9.5 vs. 9.8 months) but not OS (27.4 vs. 27.5 months) than younger patients. High tumor grade (G3/4) was associated with a shorter PFS, T4 classification with both shorter PFS and OS. Fluoropyrimidine (FP) chemotherapy backbones (doublets and single) had comparable outcomes, while patients not receiving FP backbones had a shorter PFS. In multivariable analysis, age and non-FP backbone were associated with inferior PFS, T4 classification and therapy line >2nd were significantly associated with poor PFS and OS.
Conclusion: The observed survival rates confirm previous studies and demonstrate reproducible benefits of combination bevacizumab regimens. Classification T4, non-FP chemotherapy backbone, and age >65 were associated with inferior outcome.
Document type: | Article |
---|---|
Journal or Publication Title: | Digestion |
Volume: | 94 |
Number: | 3 |
Publisher: | Karger |
Place of Publication: | Basel ; Freiburg |
Date Deposited: | 04 Nov 2019 10:52 |
Date: | 2016 |
ISSN: | 0012-2823 (Druck-Ausg.), 1421-9867 (Online-Ausg.) |
Page Range: | pp. 129-137 |
Faculties / Institutes: | Medizinische Fakultät Mannheim > Medizinische Klinik - Lehrstuhl für Innere Medizin II Service facilities > German Cancer Research Center (DKFZ) |
DDC-classification: | 610 Medical sciences Medicine |
Uncontrolled Keywords: | Bevacizumab , colorectal cancer , combination chemotherapy , elderly patients , prognostic factor |
Additional Information: | Dieser Beitrag ist aufgrund einer (DFG-geförderten) Allianz bzw. Nationallizenz frei zugänglich. This publication is freely accessible due to an Alliance licence and a national licence (funded by the DFG, German Research Foundation) respectively. |